Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $8.00 at Truist Financial

Perspective Therapeutics (NYSE:CATX) had its target price reduced by investment analysts at Truist Financial from $10.00 to $8.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 231.95% from the company’s previous close.

Several other research firms also recently commented on CATX. Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Scotiabank assumed coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $12.50.

Perspective Therapeutics Trading Up 11.6%

NYSE CATX opened at $2.41 on Wednesday. Perspective Therapeutics has a one year low of $1.60 and a one year high of $16.90. The stock has a 50-day moving average of $2.24 and a 200 day moving average of $3.77.

Insider Activity

In related news, Director Robert F. Williamson III acquired 22,192 shares of the stock in a transaction dated Friday, March 28th. The shares were purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the transaction, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This represents a 45.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Juan Graham bought 33,333 shares of the firm’s stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This trade represents a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock valued at $256,344 in the last ninety days. Corporate insiders own 3.72% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CATX. JPMorgan Chase & Co. raised its stake in Perspective Therapeutics by 24.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock valued at $333,000 after purchasing an additional 4,844 shares during the period. Taylor & Morgan Wealth Management LLC raised its stake in Perspective Therapeutics by 86.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 56,000 shares of the company’s stock valued at $179,000 after purchasing an additional 26,000 shares during the period. Trueblood Wealth Management LLC raised its stake in Perspective Therapeutics by 37.0% during the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after purchasing an additional 6,000 shares during the period. SG Americas Securities LLC raised its stake in Perspective Therapeutics by 41.3% during the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock valued at $83,000 after purchasing an additional 7,627 shares during the period. Finally, Wealth Effects LLC raised its stake in Perspective Therapeutics by 186.8% during the 4th quarter. Wealth Effects LLC now owns 38,000 shares of the company’s stock valued at $121,000 after purchasing an additional 24,750 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.